VICTORIA, April 2,2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the expansion of their service offerings in therapeutic antibody discovery to select rare, fully human antibodies using DeepDisplay™, a combination of transgenic animal immunization and custom phage display antibody selection.
ImmunoPrecise has launched, in response to a large-scale discovery program with an unnamed, US-based Pharma company, a powerful and unique platform for therapeutic antibody discovery proven to be successful in delivering a sequence-diverse human antibody panel with broad species cross-reactivity (e.g. mouse, primate, human). The combination of a transgenic animal immunization with phage display antibody selection used in DeepDisplay™ delivers the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of success compared to conventional technologies.
“The ability to select needle-in-the-haystack antibodies using this powerful combination of OmniAb® rodent (mouse or rat) immunization and phage display antibody selections provide an entirely new avenue in therapeutic antibody discovery.” said Debby Kruijsen, Ph.D., General Manager of ModiQuest® Research.
Jennifer Bath, Ph.D., President and CEO of ImmunoPrecise added: “With over 15 years of experience in customized and precision-based phage display, IPA has coupled this powerful technology with Ligand’s OmniAb® transgenic rodent platforms to enable the accelerated discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy and the lowest immunogenicity.”
The data generated during the large pharma and OmniAb collaboration will be publicly presented at conferences in Munich, Germany https://www.hub-xchange.com/europe-2019 and Boston, Massachusetts https://www.hub-xchange.com/us-east-coast-2018, in March and May, respectively, as well as via live webinar, details forthcoming.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.
The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2018 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
For investor relations please contact:
Frederick Chabot, Phone: 1-438-863-7071, Email:
Also in Industry News
Copyright © 2019 Ya-Ni Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Eosinophil asthma is characterized by the infiltration of eosinophils to the bronchial epithelium. The toxic cationic protein released by eosinophils, mainly major basic protein (MBP), is one of the most important causative factors of epithelium dama...
During metastasis cancer cells are exposed to potentially destructive hemodynamic forces including fluid shear stress (FSS) while en route to distant sites. However, prior work indicates that cancer cells are more resistant to brief pulses of high-level fluid shear stress (FSS) in vitro relative to non-transformed epithelial cells. Herein we identify a mechanism of FSS resistance in cancer cells, and extend these findings to mouse models of circulating tumor cells (CTCs). We show that cancer cel...
IJMS | Free Full-Text | The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma
Next Article in Journal
New Innovations in Wound Healing and Repair
Previous Article in Journal
Crude α-Mangostin Suppresses the Development of Atherosclerotic Lesions in Apoe-Deficient Mice by a Possible M2 Macrophage-Mediated Mechanism
Previous Article in Special Is...